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Pharmacy prescribing policy in Israel has been negotiated and changed in recent years in order to improve patient
treatment and access to medicines, and reduce national health insurance costs by allowing pharmacists to prescribe
medications. Various stakeholders and institutions were involved in the formulation process, affecting the process while
representing different motives. The complexity of pharmacy prescribing policy formulation is universal - any policy project
needs, for strategic and tactical reasons, to acquire an inventory of institutions involved, identify the key players and
explore potential support or opposition among them. This article uses the field (theory) of new institutional economics to
explain the process of pharmaceutical institutional change and identifies the stakeholders who are involved in the reform.
In the framework of pharmaceutical policies, seven models of prescribing practices are outlined, and the Canadian and
British prescribing models are presented. The paper then focuses on the Israeli case and the main issues that concern
decision-makers in the Israeli health system, such as inequality in access to health services and the erosion of the notion of
universal health services. These concerns and the involvement of different stakeholders, such as The Israeli Medical
Association (IMA) and health funds, influenced and directed the final Pharmacist Prescribing Law. After several rejections
and amendments the law was passed, enabling experienced pharmacists to prescribe only to patients with a previous
prescription given by a physician in the hope it would improve services to patients and reduce physicians’ workloads. Here,
the topic of the new prescribing policy is introduced, using tools from the new institutional school in political economy.
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Introduction
According to the literature in the field, governance in the
health sector is difficult to define as governance operates
at many different levels [1, 2]. At the broadest level, gov-
ernance can be analyzed in terms of political actors who
compete and collaborate to establish public policies [1].
At a secondary level, governance can be analyzed in terms
of the forms of these specific public policies; the resulting
rules, laws and institutions. The multilateral relationship
among clients, regulators, payers and providers that exists
in the health sector adds to the complexity of governance
arrangements in the pharmaceutical sector [3]. The main
focus of these arrangements is on transparency in the use
of public funds for buying drugs, fair and equitable access
to medicines, patients’ safety in the use of drugs, quality
assurance throughout the supply chain and the cost effect-
ive use of drugs [3]. The United Nations proclaims that a
country has good governance when its public sector acts
according to principles of transparency, accountability and
responsiveness [4].
Most literature regarding the governance of pharmaceuti-
cals reviews health systems in countries that use single paid
systems for their funding and where decisions related to
pharmaceutical issues are made directly by their Ministries
of Health [5–7]. In most countries, the profession of phar-
macy is subject to professional regulation. A pharmacists’
association, a national professional organization for
pharmacists, provides continual professional programs
for pharmacists and keeps a register of those working in
the profession. In order to practice, pharmacists must be
registered with the association [8–10].
The Israeli health system is characterized by four pri-
vate competing nonprofit health plans. They compete
over the quality of care covered by a uniform package of
benefits that is defined by the law. This package of bene-
fits is decided by the government and financed by co-
payments, an earmarked health tax as well as transfers
from the general public revenues. The periodic strategicCorrespondence: yarivhila@gmail.com
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planning and development of new policies is carried out by
external, highly visible, temporary commissions appointed
by the Ministry of Health [11], and pharmacists do not
need to be registered with any pharmaceutical associ-
ation before they can practice pharmacy [12]. In terms
of public health policy, Israel is heterodox as it has very
high defense spending due to its potential security needs
but low health spending. This normally causes a heavy
constraint on the public budget and led to popular pro-
tests in 2011 [13]. In their article, Reeves and Stuckler
comment on the need to recognize that the chronic
underinvestment in public health in Israel is a problem
[13]. This uncommon attribute adds heterogeneity to
the currently existing literature in the field of govern-
ance in the pharmaceutical sector.
The main aim of this paper is to explore what factors
are at play in the Pharmacist Prescribing Policy process
and to find out which actors were involved in the evolu-
tion of policy making, using the field of new institutional
economics to explain the process of institutional change.
Within the framework of governing the pharmaceutical
sector, the focal point of this paper is the Healthcare Policy
of pharmacist prescribing. This will contribute to a more
complete understanding of the dynamics involved with dif-
ferent stakeholders.
Israelis enjoy higher life expectancy and have a much
younger demographic profile than citizens of most OECD
countries [14–16]. Nonetheless, the demand for healthcare
is expanding rapidly due to population growth and aging,
and the country’s wide socio-economic divisions are
reflected in differences in health outcomes [17, 18]. Re-
search conducted in Israel found that prescription drugs
are the second health expenditure that people cut back on
after dental work when facing the risk of poverty [19]. Stud-
ies conducted by Degani and Degani have shown that the
proportion of individuals forced to give up prescription
drugs because of their high prices was 17 % among those
with a low socio-economic background, 12 % among those
from the middle class and 10 % among individuals with a
high socio-economic level. In addition, these studies
showed that the proportion of those giving up prescrip-
tion drugs was higher in the peripheral areas than in
the centre of the country [20]. The findings of the re-
search by Brammli – Greenberg et al. concluded that giv-
ing up medical treatment is a sign of a high degree of
poverty. Among individuals with a low income, 20 % of the
respondents had gone without medical treatment, medica-
tion or both [21, 22]. From a policy perspective, the inter-
pretation of the relationship between socio- economic
status and health implies that policies should improve
access to health care, adherence to treatments, and the
quality of care for patients with low socio-economic status.
The first section of this paper, Conceptualizing Stake-
holders, introduces concepts related to stakeholders and
institutions. The second section of the paper, Prescribing
Solutions Worldwide, outlines seven models of prescrib-
ing practices identified by the writer and briefly high-
lights pharmacist prescribing solutions in Britain and
Canada. The third section of the paper introduces the
Israeli case of pharmacist prescribing policy. The fourth
section discusses the achievements to date and presents
future challenges.
Conceptualizing stakeholders
This section introduces the concepts of institutions and
stakeholders and casts light upon the stakeholder theory
of governance, which attempts to explain how organiza-
tions can prioritize and manage relations with identified
stakeholders. The section then focuses on institutions as
social arrangements and concludes by describing the frame-
work of Pharmaceutical Policy in Israel.
Governments establish the legal framework and enforce
regimens that provide frameworks of actions for stake-
holders and their organizations, processes that institutions
have a great interest in. Scott [23] defines institutions as
multifaceted, durable social structures, made up of sym-
bolic elements, social activities and material resources.
The literature of policies on healthcare systems abounds
with references to institutional and stakeholder analysis,
which reflects the importance of the policy making pro-
cedure and the problems that it is meant to deal with
[24–26]. Indeed, any policy project, for strategic and
tactical reasons, needs to acquire an inventory of insti-
tutions involved. With this purpose in mind, the writer
identifies the key players involved in pharmacist pre-
scribing policy, explores potential support or opposition
among them and highlights the relevant institutions’
roles and the inter institutional linkages [27].
The term ‘prescribing’ used in this paper is as used by
the National Nurse Prescribing Glossary (which was, in
turn, adapted from: the National Health and Medical Re-
search Council (1998): “the provision usually in writing by
an authorized prescriber, after clinical assessment of a spe-
cified patient/client, of instructions for the dispensing or
administration of medicine for that specified patient/client.
Legal authority to prescribe required” [28]. Through-
out this paper, the writer describes prescribing as an
act that requires the knowledge of applied pharmaco-
kinetics, adverse effects, optimal routes, doses, drug-food
and drug-drug interactions, pharmacodynamics and mon-
itoring of effects. Application of this knowledge requires
significant expertise. The clinical skills that are involved in
the process of prescribing include: deciding that a drug is
indicated, choosing the most appropriate drug, deciding a
dose and schedule appropriate for the patient’s physio-
logical status, educating the patient about possible adverse
effects, monitoring for toxicity and effectiveness and indi-
cations for seeking further consultation [29].
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In this paper, the term stakeholder means groups or per-
sons whose interests and activities strongly affect and are
affected by issues concerning those who have a ‘stake’ in
change, who control relevant information and resources
and whose support is needed in order to implement the
change [30].
A stakeholders theory addresses morals and values in
managing an organization. The theory also explains and
describes the web of stakeholders’ relationships that in-
evitably emerge within governance [31, 32]. In the case
of pharmacist prescribing policy, ministers, various depart-
ments of ministries, regulators, health fund representatives,
physicians, pharmacy unions, lobbyists, expert commissions
and advisers interact within the official process of legislating
pharmacist prescribing law. Each player hopes to advance
their own agenda. Consumer health organizations and
interest groups also interact under government aus-
pices to influence health policy outcomes. This web of
networking stakeholders, deliberating and negotiating,
is a fundamental force needed to drive health policy re-
form [33, 34].
New Institutional Economics (NIE) incorporates a the-
ory of institutions into economics. It has been developed
as a movement within the social sciences, especially eco-
nomics and political science [35, 36]. It unites theoretical
and empirical research, examining the role of institutions in
furthering or preventing economic growth. Douglass North,
a professor at Washington University’s Department of Eco-
nomics in St. Louis, MO, has led groundbreaking work on
how institutions and societies interact and how those inter-
actions can positively or negatively impact economics as
they evolve over time [35].
North defines institutions as the humanly devised con-
straints that shape human interaction and calls for the
analytical distinction between the rules of the game (insti-
tutions), the players of the game (individuals and organiza-
tions), and the way the game is played [35]. Pharmacy is a
classic field in which to test and study NIE, as this profes-
sion is institutionally constrained by environmental factors
such as medicine policies, demand for sales of over-the-
counter medicines, pharmacy services provided, institu-
tional boundaries such as the pharmacy regulation act,
drug laws and regulation of drug entry and rules on exer-
cise of the profession [37]. Consequently, the writer views
the professional group of pharmacists as “players” who play
to achieve better role recognition. Pharmacy is their
“game”, which is played in the field of the changing health-
care environment.
In comparison to past services, the pharmacist’s ser-
vices of today include more patient-oriented, administra-
tive and public health functions [38, 39]. Therefore, the
pharmacist’s role is expanding beyond the traditional
product-oriented functions of dispensing and distribut-
ing medicines and health supplies. The aim of the Israeli
Pharmacist Prescribing Policy, the focus of this article, is
to improve patient access to medicines, making the best
use of pharmacists’ clinical competencies. From a govern-
mental point of view, objectives such as reducing waiting
times for physicians, reduction in medications errors and
wastage may lead to cost savings in the long run. North
[40] also provides a historical perspective on the influ-
ence of different paths of institutional change on economic
development. Institutional change is dependent upon (1)
how different groups perceive possible opportunities and
threats posed by alternative paths of institutional change or
stagnation to their interests, and (2) their local, national
and international political effectiveness in influencing
the pace and path of institutional change.
A framework of pharmaceutical policy in Israel
The term “pharmaceutical policy” describes the conscious
efforts of national governments to influence the function-
ing of pharmaceutical subsystems [41].
Governments register medicines, compile essential medi-
cines lists, license manufacture, procure supplies for the
public sector, and dispense a substantial share of medicines
through public and private facilities. In addition, they
regulate prices and staff qualifications, inspect medi-
cines for quality, collect taxes and train pharmaceutical
personnel [42]. The resulting complex collection of rules,
financing choices, regulatory decisions and laws constitute
a nation’s pharmaceutical policy. The objectives of pharma-
ceutical policy vary for countries of different income levels.
In low income countries, the most prevalent objective is to
secure the population’s access to essential medicines. For
middle income countries, the objectives are to access a
broader range of medicines and to develop industry in
the pharmaceutical sector [41, 42]. In high income coun-
tries, the objectives are to support the innovation of new
treatments and drugs as well as provide universal access
to all important treatments [42].
In Israel, drug laws are commonly issued by the Knesset
(Parliament and legislative body), which also defines the
rules and conditions under which the pharmaceutical sec-
tor operates [43]. The Ministry of Health (the execu-
tive branch) defines the implementation guidelines and
technical standards for the law in ordinances or regula-
tions. In common with European countries, Israel enforce-
ment agencies and drug laws regulate the supply side
parameters of the pharmaceutical market (research, qual-
ity assurance, licensing of products, promotion), while the
demand side is typically regulated by legislative instru-
ments which define who pays for which drugs and under
which circumstances [44]. An example of such a legislative
instrument is the Israeli Health Insurance Law. Other regu-
lations and laws such as antitrust laws and trade laws
may also influence the pharmaceutical sector. Further-
more, soft law and sectorial agreements consist a framework
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for pharmaceutical policy. During 2014, an updated joint
treaty between the Israel Medical Association and the repre-
sentative organizations of all pharmaceutical companies
operating in Israel was signed. Its aim was to formulate
the ethical rules underlying the professional relation-
ship between physicians and pharmaceutical companies
and to protect patients’ health and safety in this new
work environment, in which extraneous considerations
may overshadow scientific truth and interfere with med-
ical decisions in the name of foreign interests [45].
Thus, policy makers need to consider these issues as
well when making a policy decision. The work of expert
commissions is governed in the ordinance and other
relevant laws.
Pharmacist prescribing solutions
This section records the rising costs of healthcare as well
as the total volume and costs of prescribing, and presents
a practical solution, namely the Pharmacist Prescribing
Policy. This is followed by the introduction of seven differ-
ent prescribing models that exist worldwide. The section
concludes with a description of the British and Canadian
pharmacist prescribing models that have been in place
since 2003 and 2006, respectively.
Total prescription sales in the United States for the
12 month period ending on September 30th, 2013 were
326 billion U.S. Dollars, which was slightly lower than
the previous 12 months (−0.7 % growth) [46]. In the
U.K, prescription costs were 6199.70 million British Pounds
in the 12 months between August 2012 and August 2013.
Prescription volume in the same time period accounted for
740 million prescriptions [47].
The statistics portal “Statista” gives a projection of total
prescription drug revenue worldwide from 2014 to 2020.
In 2018, the industry is expected to generate 926 billion
U.S. dollars in prescription drug revenue worldwide. This
includes the leading 500 pharmaceutical and biotechnol-
ogy companies and is expected to reach over one trillion
U.S. dollars by 2020 [48].
There are several key issues involved in policymakers’
concerns about the viability of our healthcare systems
today. These include the increased cost of new pharma-
ceuticals and other evolving technologies, the growing
needs of aging populations, the impact of chronic dis-
eases, and a significant workforce crisis [49]. Solutions
to these issues will not come easily; however, what is clear
internationally is that pharmacists, who are viewed as drug
experts, can become key participants in the management
of health care costs through their contribution to the in-
formed and appropriate use of medications in community,
hospital and nursing home settings [49, 50]. Pharmacists’
involvement in optimizing drug therapy is shown to pre-
vent hospitalisation by identifying inappropriate medica-
tion use in older adults, by improving anticoagulation
outcomes in pharmacist led anticoagulation clinics and
by promoting medication adherence with a reduction
in cardiovascular risk factors in pharmacy education
programs [51].
Starting in the 19th century, governments reacted to con-
cerns about drug misuse and public safety by using medi-
cine regulation legislation. In the early part of the 20th
century, prescriptive authority was limited in legislation
to vets, dentists and physicians. In the latter part of the
same century, a vast range of medicines on the market
was used for prophylactic and treatment purposes. The
scope for treatment was expanded and the focus shifted
to methods of funding health while assuring timely and
safe access to medications. One of the ways to deliver
this was to expand the prescribing authority of health
care professionals other than physicians [52].
Models of prescribing
A review of the international pharmacy literature identifies
seven models of prescribing practice. These demonstrate
the potential breadth of practice and the capacity of phar-
macists to initiate modify and monitor prescription medi-
cine use with varying levels of autonomy.
Independent prescribing by pharmacists
Independent prescribing by pharmacists occurs when the
prescribing practitioner, who is a pharmacist, is solely
responsible for patient assessment, diagnosis and clin-
ical management. This position requires legally defined
levels of knowledge and skills that are usually moni-
tored through a licensing process. This model is currently
implemented in Australia as well as in the UK [39, 53].
Dependent prescribing models: prescribing by protocol
‘Dependent’ prescribing incorporates further restrictions on
prescribing activities, via protocols or formularies. Prescrib-
ing by protocol is the most common form of dependent
prescribing, and is defined as delegation of authority from
an independent prescribing professional, usually a physician
[54]. The protocol is a written guideline that describes the
activities pharmacists may perform in their prescriptive au-
thority1 . The protocol details the procedure plan that the
pharmacist must follow when prescribing, as well as the
types of diseases, drug categories, the responsibilities of
each of the parties involved, and prescriptive decisions
covered by the agreement [54]. Studies propose that
prescribing by protocol improves access to medicines
as patients do not need to visit their physician and also
reduces drug costs as the prescriber is restricted to
prescribing according to a specified treatment protocol,
based on available evidence and for patients with a par-
ticular diagnosis [55, 56].
Yariv Israel Journal of Health Policy Research  (2015) 4:49 Page 4 of 13
Dependent prescribing models: Patient Group Directions
A Patient Group Direction (PGD) is a written direction
signed by a doctor or a dentist, as well as by a pharma-
cist, relating only to supply and administration of prescrip-
tion medicine. The PGD applies if a number of specified
requirements are met and is subject to any specific ex-
clusion listed. Only specific drugs listed in the PGD are
allowed to be prescribed [55]. This policy has been im-
plemented for the prescribing of hepatitis vaccinations
for drug misusers in the UK [57].
Dependent prescribing models: prescribing by formulary
In formulary-based prescribing, local formularies are set
between participating community pharmacies and med-
ical practitioners. The formulary includes a limited list
of medicines and the length of treatment, treatable symp-
toms, criteria for referrals and limitations on prescribing.
Considerable record-keeping is needed as well as an extra
pharmacist and private consultation area [55]. This is cur-
rently implemented in Florida for a skin patch which is
used to prevent nausea and vomiting caused by motion
sickness [58].
Dependent prescribing models: repeat prescribing by
pharmacist
Repeat prescribing by pharmacist involves pharmacists
providing medication-refill services in clinics associated
with medical centres, for patients who have exhausted their
prescribed drugs before their next physician appointment
[59, 60]. There are few optional services that are available
according to this model. According to one optional service,
the pharmacist examines the patient and the therapy and
then either refills the medication with a sufficient quantity
to last until the next available appointment or consults the
attending physician if there are problems with compliance
or side effects [60]. According to a second option, a
pharmacist can prescribe a further supply of medicines
that were initially prescribed by a physician after con-
ducting an effective patient – centred consultation and
being satisfied that the medicines are safe and effective.
Often, there are restrictions in terms of the number of
prescriptions per patients that are allowed to be pre-
scribed by the pharmacist and regulations may restrict
some types of drugs from being prescribed. In line with
this prescribing service, the pharmacist is required to
review patients’ current treatments and conditions, and
use his clinical judgment and effective consultation
skills to decide whether it is safe or not to provide the
patient with a prescription for the continuous supply
of his/her medicines. The implementation of this pre-
scribing model is underway in Israel and already exists
in Australia [61]. The main value of this model is that
it provides improved access to medicines, using pharma-
cist knowledge to evaluate the appropriateness of existing
medications and providing continuity of care for patients
with chronic diseases. The disadvantage of this model
is that currently in Israel, only pharmacists who work
in health funds pharmacies are able to access patient
medical records, whilst pharmacists working in commu-
nity chain and privately owned pharmacies, are unable to
access these records.
Dependent prescribing models: supplementary prescribing
Supplementary prescribing, is a voluntary partnership be-
tween the independent prescriber and a supplementary pre-
scriber, to implement an agreed patient-specific clinical
management plan (CMP) with the patient’s agreement
[62]. The independent prescribers are physicians or den-
tists who undertake the initial assessment and the supple-
mentary prescribers are registered pharmacists or nurses
who then write the prescriptions [63]. The CMP provides
detailed guidance for each stage in the management of a
patient with a specific condition over a given time period,
and includes progress and outcomes details. This type of
prescribing is tailored to patient’s needs and is therefore
believed to improve clinical outcomes and help reduce
costs by shortening hospital stays due to comprehensive
medication reviews with the pharmacist that contributes
to increased patients compliance and improved patient
safety. A further benefit of the model is the improvement
in multidisciplinary communication, teamwork and care
planning between health sectors [59].
Collaborative prescribing models
Collaborative prescribing requires a cooperative practice
relationship between a pharmacist and a physician or prac-
tice group, with legal authority to prescribe medications.
Explicit collaborative agreements are negotiated within each
facility, outlining who is receiving authority and delegating,
and a demonstration of competence. Firstly, the physician
diagnoses and makes initial treatment decisions for the pa-
tient, and secondly selects, initiates, monitors, modifies and
continues or discontinues pharmacotherapy as appropriate
to achieve the agreed patient outcomes. The physician and
pharmacist share the risk and responsibility for the patient
outcomes. Collaborative prescribing is used in several
countries such as France, Switzerland, and almost all
states in the US [64].
This next section follows reports from the American
Pharmacist Association and focuses on two countries,
Britain and Canada, where the healthcare innovation of
extending prescribing authority was driven by different
factors [65]. In Britain, the driving force was the need to
improve services to vulnerable groups such as the elderly
and the disabled. In Canada, the driving factor for pharma-
cist prescribing was the shortage of physicians in remote
areas [65]. Israel has longevity in common with Britain
and a shortage of physicians in peripheral areas in common
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with Canada. According to the Central Bureau of Statistics
(CBS) population projections, the elderly population in
Israel is expected to reach 1.367 million in 2030 – a 84 %
increase on the 2009 figure [66].
The introduction of a pharmacist prescribing policy
provides a new facet of improved accessibility to eld-
erly patients in primary care. The Israel Medical Asso-
ciation reports that there is a disparity between the scopes
of healthcare services available in the periphery compared
to central Israel. One of the most complex problems with
health services in the periphery is the difficulty in attracting
medical and nursing manpower from central Israel [67].
As pharmacists are available for consultation when other
care providers are geographically inaccessible, pharmacist
prescribing has great potential to immensely improve the
health of Israelis. Therefore, pharmacists can play a role in
eliminating and addressing health disparities.
Pharmacist prescribing model in Britain
There are two models of pharmacist prescribing in Britain.
Pharmacist Supplementary Prescribing (SP) was introduced
in 2003 and involves a voluntary partnership between the
responsible independent prescriber (a physician or a
dentist), the supplementary prescriber (most commonly
a pharmacist or a nurse) and the patient. As part of the
prescribing process there is a need to implement an agreed
patient-specific clinical management plan (CMP) [10, 62].
Time spent initially developing a simple CMP eventually
saves time when the patient returns for review to the
supplementary prescriber rather than to the physician.
Pharmacist independent prescribing (IP) was introduced in
2006. In this model, the pharmacist is the sole prescriber
responsible for the assessment and consequent manage-
ment of the patient’s condition [62].
The legal basis of supplementary prescribing was the
Health and Social Care Act of 2001 which enabled the
government to extend prescribing responsibilities to other
health professions. Amendments to the Prescription Only
Medicines Order and NHS regulations allowed supple-
mentary prescribing by suitably trained nurses and phar-
macists from April 2003 and podiatrists, physiotherapists
and radiographers from 2005 [68]. The objective of the
model was to provide patients with quicker and more effi-
cient access to medicines while making the best use of the
clinical skills of eligible professionals. In the government’s
view, the aim of the policy was to reduce doctors’ work-
loads, giving better opportunity to tend to patients with
complicated conditions and complex treatments [62].
The main facet of the model is maintaining communica-
tion between the independent and supplementary pre-
scribers, allowing them to consult, update, share access to
the same local or national guidelines or protocols, agree
and share a common understanding of and access to the
written CMP [63].
In terms of education, a pharmacist who is trained to
become a supplementary prescriber is asked to under-
take a specific training program at degree level. The pro-
gram comprises approximately 25 taught days plus at least
12 days ‘learning in practice’ [53].
At first, the formulation and implementation of Pharma-
cist Supplementary Prescribing was met with strong oppos-
ition from the medical community. The World Medical
Association added that certain tasks can only be per-
formed by physicians, prescribing being one of those
things [63]. However, the program is now considered to
be well-integrated and to have greatly contributed to
patient care which is safe and of good quality [53, 69].
Pharmacist prescribing model in Canada
Traditionally in Canada, the authority to prescribe medica-
tions has rested with a small number of professions. With
changes to legislation or regulations in most Canadian
provinces over the past eight years, many pharmacists
now have the ability to initiate, continue or modify drug
therapy, ranging from renewing a continuous care prescrip-
tion to independent prescriptive authority [70]. In 2013,
community pharmacists prescribed for flood victims in
Calgary who had to evacuate their homes in the middle
of the night, leaving their medications behind [65].
The Canadian Association of Pharmacist Prescribing re-
ports that medication adherence is particularly a challenge
for the treatment of chronic conditions in Canada. As
most provinces limit prescription length to three months,
four million Canadians report not having a regular phys-
ician nor access to primary care doctors for the purpose of
their prescription renewal. The Association supports the
granting of pharmacist prescribing authority to improve
medication adherence by making refills and emergency
supplies more readily available to these patients [70].
A comprehensive policy review and comparison of docu-
ments and regulations written by the relevant government
and professional agencies in Canada shows that in terms of
pharmacist prescribing, legislative or regulatory enactment
of current privileges are in place or expected in the future
across different provinces [65, 70]. Findings show that sub-
stantial variation exists in the scope of pharmacy practice
across provinces as provincial pharmacy regulatory bodies
vary in governance structure, legislation and standards and
codes of conduct [54]. Overall, prescribing policies have
three typical forms: firstly, allowing pharmacists to re-
new prescriptions for long-term conditions, secondly,
permitting short-term dispensing to allow patients to
continue therapies uninterrupted and thirdly, allowing
pharmacists to prescribe in emergency situations. In
addition, existing provincial policies also vary in the type
of formal and experiential education required of prescrib-
ing pharmacists as well as in terms of knowledge, skills
and continuous professional development [50, 70].
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To that end, Israeli policy-makers can learn from the
cases of these two countries and ascertain the determi-
nants of success in obtaining pharmacist prescribing
reform in Israel.
An integrative review of literature on non-medical pre-
scribing in primary care undertaken by Bhanbhro et al.
[59] shows that in the 21st century non-medical prescrib-
ing has evolved differently in different countries. The study
demonstrates that out of the 193 countries that are mem-
ber states of the World Health Organization (WHO),
twenty countries provide legal authority to nurses and
other health professionals to prescribe medications,
while other countries are considering introducing le-
gislation. With respect to stakeholders’ acceptance of
the new pharmacist prescribing role, studies show that
health professionals and patients widely approve and
view positively the non-medical prescribing initiative
[39, 59, 71].
Five models for Pharmacist Prescribing have been iden-
tified and deemed suitable by the Israeli Knesset during
the policy formulation stage: repeat prescribing model,
prescribing for minor illness model, emergency pre-
scribing model, prescribing by protocol and independ-
ent prescribing [72]. After much deliberation in the
Knesset, it was decided that, initially, the only prescribing
to be put into practice would be the repeat prescribing
model. According to this model, during a prescribing con-
sultation, the pharmacist interviews, listens and examines
the patient’s medical records, then checks the current drug
therapy to decide whether it is safe to issue a prescription
with a further supply of medicines, that were initially pre-
scribed by a physician, or refers him back to his physician
for a further consultation. The IMA shared an objection
to the rest of the models, thence most were postponed in-
definitely. However, the Knesset’s chairman and the head
of the Health Ministry agreed that the prescribing for
minor illness (such as coughs, allergic reactions, sunburn
and skin infections) would be revisited once the implemen-
tation of the repeat prescribing model was complete [73].
The Israeli case
This section unfolds the story of the pharmacist prescribing
initiative in Israel. It begins by pointing out the essentiality
of the policy to the Israeli health system and continues by
revealing the process of agenda setting. The section then
describes the chain of events that resulted in policy formu-
lation and identifies the key objectors to the policy.
To date, the Israeli health-care system, centered on four
health funds (to the tune of 95 % of the total market), is
widely acknowledged as providing a “package” of universal
services of good quality primary and secondary care, while
also accommodating demand for private health care
[74, 75]. Nevertheless, there are challenges and tensions
in the system. In recent years, the authorities have worked
to expand the number of students trained in medical
schools and nursing training as large cohorts of health-
care professionals are heading for retirement [76]. Media
reports and public opinion polls show that Israelis are dis-
satisfied with the amount of time people wait to receive
medical care [77, 78]. As a consequence, the demand for
health care services exceeds the supply of those services
and some measures must be taken to allow better access
to health care. An example of such a measure, exploiting
opportunities to shift tasks from physicians to pharma-
cists, is the case of the Pharmacist Prescribing Initiative.
Entrusting pharmacists with more responsibilities is likely
to reduce current demand on other, more expensive health
care resources such as hospital emergency rooms and
physicians. A study investigating pharmacists’ perceptions
of the value of pharmacist prescribing of antimicrobials in
hospital settings in Scotland found that “optimization
of antimicrobial use through pharmacist prescribing of
antimicrobials was also perceived as indirectly leading
to a reduction in overall costs through shorter bed stays,
using cheaper but same-spectrum antimicrobials, ensuring
appropriate duration and switching to oral use when
feasible” [79].
Concerns about strict practice policies and liability as-
sociated with prescribing are often reported. A research
article describes that to resolve these concerns, pharmacists
tend to reduce the amount they prescribed, take care to
document and take additional time to review clinical in-
formation [80]. This tight control is hoped to eventually
result in lower costs to the health system and better health
outcomes for individuals.
In Israel, the potential healthcare cost savings were also
a driving force for the adoption of the policy [73]. As phar-
macists are generally on lower wages than physicians, the
2014 BMI report estimates that shifting and reducing
labor costs means that funds will be released for spend-
ing on other areas of the healthcare system. The report
foretells that prescription drug sales in 2014 are ex-
pected to amount to 1.68 billion U.S. Dollars, a 7.72 %
increase on 2013. The report further foretells that due
to favorable epidemiological factors in Israel, such as
an aging population and population growth, continued
increase in demand for drugs for chronic diseases and
physicians’ consultations is expected [14].
In July 2014, after a decade of negotiation and deliber-
ation, the regulations for the Pharmacist Prescribing Law
in Israel were finalized and the ordinance was published.
This policy is much needed as recent data shows that in-
come inequalities in Israel are wide and persisting. The
average income of the richest 10 % of the population in
Israel is about 14 times that of the poorest 10 % [81]. The
Gini coefficient for Israel, which is a measure of income
inequality ranging from zero (full equality) to 1 (when only
one person concentrates all income), is among the highest
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in the OECD [82]. The rise in private funding has been
found to affect patients’ compliance and concordance with
their medications [83, 84]. The pharmacist prescribing
initiative aims to improve adherence and contribute to
achieving better health outcomes for Israeli patients.
The 2014 Business Monitor International paper reports
that those on the lowest incomes in Israel struggle to pay
for medical services fully, despite the well-functioning uni-
versal health system [14]. As rural areas often have a greater
demographic need, research has shown that there is a link
between health disparities and rural living [36]. An OECD
review of the tackling of inequalities in health in Israel
reports that people who live in the periphery have worse
health indicators than people who live in urban areas [85].
A more recently published OECD report highlights the
wide variations in healthcare in Israel. The findings suggest
that either unnecessary care is being delivered in areas of
urban living, or that there is unmet need in rural regions
[86]. Thus, local pharmacists are particularly valuable as-
sets in impoverished urban areas. The Pharmacist Prescrib-
ing healthcare policy aims to resolve these issues as will be
outlined in this article.
Studies have shown that creating channels for stakeholder
participation in managing or supervising public healthcare
services can improve the performance of services in several
ways [27, 36]. One example is the opening of policy deci-
sions in Israel to professional associations to protect health
professionals’ interests and safeguard the medical quality of
care. Since Israel does not have a comprehensive national
health plan or an active system for setting and updating na-
tional health targets, periodic strategic planning and devel-
opment of new policies are carried out by external, highly
visible, temporary commissions appointed by the Ministry
of Health [11]. In his report, Rosen names several Israeli
health-related commissions and adds that due to the Minis-
try of Health’s multiplicity of roles, the latter’s commissions
are perceived as being able to examine issues related to
healthcare closely, efficiently and objectively [11].
The journey towards extending pharmacists’ responsi-
bilities began in 2000 when the National Board to pro-
mote the pharmacy profession, named the Benita Board,
was commissioned by the Ministry of Health with the
aim of discussing the future of the pharmacy profession
in Israel. The board was the first to introduce the idea of
extending pharmacists’ responsibilities by giving pharmacist
prescribing authority [87]. To make this happen, an amend-
ment to the existing Pharmacists’ Ordinance (new version -
1981) had to be made.
In 2006, the Ministry of Finance’s proposal sought to
amend the Pharmacists’ Ordinance (new version – 1981)
so that it would enable a pharmacist to issue a prescription
drug not based on a prescription signed by a physician, and
to amend the Physicians’ Ordinance (new version – 1976),
so that the authority of the Director General of the Ministry
of Health to permit individuals who are not physicians to
perform extraordinary medical procedures will be expanded
to para-medical professionals [88]. It was decided that a
joint committee of the Ministry of Finance and the Ministry
of Health would be established with the aim of determining
which medical activities, currently performed only by doc-
tors, would be authorized for pharmacists, nurses or para-
medical professionals. The Ministry of Finance believed
that the policy would save physicians’ time and reduces
pressure through sharing the patient load. The emer-
ging data at the time, which compared the cost of pharma-
cist prescribing to physician prescribing, demonstrated that
one of the benefits of the scheme was that pharmacist pre-
scribing proved to be more cost effective [39, 59]. The
Golomb Committee was commissioned to find possible
ways to assimilate the amendment to the Pharmacists’
Ordinance and to suggest possible ways to regulate pre-
scribing as well as dispensing medicines not in accord-
ance with physician prescription. Within a short period
of time, a new ordinance was suggested to allow phar-
macists to prescribe, but it has since been invalidated
by the Justice department by the claim that it diverges
from the provision of the present law and creates a new
professional entity not defined by it. As a result, The
Knesset rejected the ordinance [89].
In 2009, the Pharmacists’ Ordinance was amended once
again. This time it was passed successfully in the Knesset
as part of The Arrangements Law, a government bill that
is presented to the Knesset each year alongside the Budget
Law. It incorporates government bills and legislative
amendments that are needed in order for the govern-
ment to fulfill its economic policy [90]. The Arrangements
Law is a unique instrument used by the government to ini-
tiate legislation, complete legislative acts and stall or elim-
inate private members’ bills already being legislated. In
essence, through the law, the government can overcome
parliamentary obstacles, as it does not need to be approved
by the various committees, as ordinary bills usually do. It
was not until 2011 that the amendment to the existing law
was approved. During 2011, the advocates of the Pharm-
acist Prescribing Policy encountered a further obstacle
raised by a second stakeholder, namely the Israeli Law, In-
formation and Technology Authority (ILITA). The ILITA
was established by the Ministry of Justice to become
Israel’s data protection authority. After much debate be-
tween the ILITA, the Pharmaceutical Society of Israel and
members of the Ministry of Health, a new version of the
law with an amendment concerning the protection of data
shared during the prescribing process was introduced [91].
In 2014, the Pharmacist Prescribing Policy was final-
ized and the regulations that will enable pharmacists to
prescribe were approved. The ordinance specifies various
conditions for prescribing to take place, four of which
are listed here. Firstly, it was decided that in the first
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stage of implementation, pharmacists will only be able
to prescribe medications for chronic conditions that have
been previously prescribed by a physician (i.e. the repeat
prescription model as outlined previously). Many stake-
holders were disappointed to discover that only one out of
the original five models was approved by the Knesset. Sec-
ondly, it was determined that only pharmacists with a
minimum of five years’ experience will be allowed to pre-
scribe for a list of conditions such as diabetes, Parkinson’s
disease, muscle pain, thyroid disorders and urological
problems. The law allows pharmacists to issue a repeat
prescription only up to six months after the expiration
of the original prescription. Thirdly, it was agreed that
pharmacists will have to complete an eighty-hour course
and pass an exam before being able to prescribe [92]. The
first prescribing course commenced in January 2015 [93].
Finally, to support optimal medication management, phar-
macists require access to patient medical records during a
prescribing consultation. The rationale behind this is that
prescribing should also involve an accurate, legible and
comprehensive written prescription based on looking at a
patient’s drug history, accessing previous lab results and
documenting the consultation in the patient’s records to
establish the continuity of care. At present, patient medical
records can only be accessed by pharmacies that belong to
the health funds. Pharmacists who work in privately owned
pharmacies are unable to access those records.
In an interview with Mednet, The Director of the Pro-
fessional Committee of the Pharmaceutical Society of
Israel, Dr. Ron Tomer, commented that the aim of the
policy is to improve patients’ service in terms of quality
and availability of treatment, reduce physicians’ work-
loads and save on health expenses. Dr. Tomer explained
that the extension of prescribing rights will start with
pharmacists only renewing prescription drugs, being re-
sponsible for the continuing care of patients who have
been clinically assessed by a physician. “Eventually, one
hopes”, he said “that suitably qualified pharmacists could
become independent prescribers in their own right” [94].
Records show that the four health funds supported the
policy throughout the implementation stage [43]. One may
speculate that one of their motives was the future cost sav-
ings involved due to the reduction in labor costs. Finally,
the shift in prescribing policy means that physicians will
have additional time to attend to more important issues in
the six months interval between patient visits.
The Israeli Medical Association (IMA) was an influen-
tial stakeholder that opposed the Pharmacist Prescribing
Policy throughout, arguing that the prescribing policy
lacks budget ramifications and is therefore not related to
economic policy – yet it was passed through the Ar-
rangements Law, a framework whose sole aim is to deal
with budgetary and economic aspects [89]. The mem-
bers commented that the issue of transferring medical
authority is complex and has fundamental ramifications
for the state health system and for the condition of pa-
tients and therefore should only be accepted if treated
by the Knesset as a standard bill which is usually ad-
vanced in a number of stages (“readings”) until it is fi-
nally passed [89].
The patient advocacy organization was involved in the
initial stage of the legislation. Their concerns involved
securing patient confidentiality and allowing patients the
choice to decide whether to use the service or not. Once
these two issues were cleared up (patient confidentiality
was defined in the law and it was clear that the service
was optional), the organization ceased to be involved.2
Overall, the Pharmacist Prescribing Law was legislated
twice and the legislation process lasted nearly a decade,
mainly due to the opposition of various stakeholders who
were mentioned in this article. The leading argument of the
IMA was the state’s commitment to the Patients’ Rights
Law that declares the right of every patient to receive good
medical treatment with respect to the professional level and
quality of medicine [89]. According to them, the logic
underlying the singularity of medical practice according
to the Physicians’ Ordinance can be expanded to the au-
thority of others and may therefore contradict the legal
standard. They claimed that there is no substitute for the
extensive years of study and enormous professional know-
ledge accumulated by physicians in diagnosing and pro-
viding medical treatment to the patient and those health
professionals who are not physicians are not as likely to be
able to remain up-to-date with the latest scientific litera-
ture. As mentioned earlier, the Independent Prescribing
model was withdrawn from the final stage of deliberation
due to the raised objection by the IMA, which has powerful
and influential status in the Knesset [73]. This was a
big setback for pharmacists.
The law was also disputed by the Labor and Welfare
Committee, which on several occasions protested against
the passing of the law through the hurried Arrangement
Law system and claimed that a much longer debate was
needed. Nonetheless, the Knesset protocols provide evi-
dence that on several occasions during the voting process,
the majority of the committee members voted in favor of
the policy [73].
When interviewed by the writer, a few different stake-
holders questioned the necessity of the pharmacist pre-
scribing service due to the fact that nowadays physicians
are allowed to prescribe “refill authorizations” that pro-
vide patients with access to medications until their next
medical visit. Their opinion was that most patients order
their prescriptions online, making the pharmacist pre-
scribing service, again, unnecessary. They claimed that ten
years have passed since the commencement of pharmacist
prescribing policy legislation and meanwhile, with the ad-
vance of the internet and the online medication ordering
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service, the policy has become redundant.3 Another, rela-
tively new technology in Israel is e-prescribing (also called
electronic prescribing) that was first introduced in 2010.
This is a technology framework that allows physicians to
write and send prescriptions to a participating pharmacy
electronically. The 2010 Milken Institute report explains
that “ in terms of CPOE (computerized physician order
entry; the process of a medical professional entering medi-
cation orders or other physician instructions electronically)
and e-prescribing, Israeli usage is 95 percent” in compari-
son to the United States, “where their usage is just 20 per-
cent” [95]. Online medication ordering and e-prescribing
services are estimated to save the Israeli economy over 11
million physician working hours per year. It is possible that
what stakeholders considered as an essential service in the
past (i.e. pharmacist prescribing) has become non-essential
with the advance in technology.
There is a consensus among the interviewed stakeholders
about the need for additional pharmacist training and staff-
ing to fulfill their new prescribing role as well as a properly
aligned incentive to compensate for these additional profes-
sional costs and for the additional value brought to the citi-
zens of Israel. To date, no such financial incentive exists.4
There was no involvement of the Israeli Pharmaceutical
Industry during the legislation process as generic substitu-
tion at the point of dispensing in both private and public
sector facilities is allowed. This is in contrast to the U.S.,
where one of the main barriers to the Pharmacist Pre-
scribing Initiative was the pharmaceutical industry’s objec-
tion to the policy, since they perceived pharmacists as
being more likely to prescribe cheap generics than physi-
cians, which will damage their sales [54].
Discussion
This article highlights recent changes to the pharmacy
regulations that will empower pharmacists to provide
prescription medications to better serve Israelis. The
Israeli patients who are most likely to benefit from the
new regulations are those who suffer from chronic condi-
tions, such as diabetes and asthma. The aim of the policy is
to provide seamless, faster care to patients to obtain their
medicines through making better use of pharmacists’ skills.
Hopefully, these regulations will improve access to medical
services and the efficiency of the health system overall [14].
Deputy Health Minister Ya’akov Litzman expects that these
regulations will allow pharmacists to fully utilize their ex-
pertise in medication management in the interests of the
wellbeing and health of Israelis, particularly those who live
in the periphery (suburbs) [87].
Stakeholders’ views on the expected economic impact
of pharmacy prescribing vary.
It is expected that the introduction of the service will lead
to cost saving in the healthcare system through reduction
in unnecessary medication use and increased patient choice
in accessing medicines. An analysis to measure the impact
on patient health outcomes and cost benefit analysis is re-
quired as this prescribing model rolls out. These results
might be key factors at play in the Pharmacist Prescribing
Policy process.
The IMA’s response to the policy can be viewed, within
the framework of challenges to medical dominance, as a lo-
gical reaction to the potential loss of professional status.
Mesler [96] notes that when some professionals [e.g. phar-
macists] obtain and deploy resources, others [e.g. physi-
cians] do not necessarily lose them. Finally, it is envisioned
that through a multi-disciplinary and collaborative ap-
proach, expanding pharmacists’ authority to prescribe
will help to achieve an optimal public health outcome.
The extent to which the Pharmacist Prescribing Policy
will be implemented successfully depends on current
policy imperatives. For instance, in 1997 the Department
of Health in South Africa withdrew pharmacists’ permits
that enabled them to provide prescription only medi-
cines at their discretion [97, 98]. In Canada there have
been several attempts to create system wide pharmacist
practice change before any reform is successful [54].
Currently, there are no mechanisms by which commu-
nity pharmacies can be reimbursed for the prescribing
service. Data gathered from interviews with key Israeli
stakeholders suggests that in their opinion, this challenge
is the biggest one to yet be overcome. Furthermore, critics
of this advance in the practice of pharmacy will not be
reassured that, under the proposed standards, it will be ac-
ceptable for a prescribing pharmacist to also dispense the
medicine that he prescribed to the patient. The lack of
separation between prescribing and dispensing questions
the pharmacists’ ability to ensure patient safety and pre-
vent any potential conflict of interest. If pharmacists are
only compensated for dispensing medications then this
may lead to the possibility that pharmacist prescribing has
an inherent conflict of interest for pharmacists. They
would be inclined to prescribe medications (instead of
eliminating unnecessary medications) so that they could
sell more drugs.
Several stakeholders were concerned about the lack of
an insurance provider who is able to provide professional
indemnity cover for the extended role of prescribing.
The need for pharmacists’ education is an additional
hurdle. Today, the prescribing course is relatively expen-
sive, lasts for six months and entails passing an exam to
qualify as a pharmacist prescriber. When interviewed,
two official stakeholders from the health funds explained
that they currently have no funds to send their pharma-
cists on the training course. On a positive note, one hun-
dred pharmacists attended the first prescribing course that
commenced in January 2015. An unpublished study con-
ducted by the writer investigates the opinions of the course
Yariv Israel Journal of Health Policy Research  (2015) 4:49 Page 10 of 13
participants regarding the benefits, challenges, facilities and
concerns regarding the introduction of the pharmacist pre-
scribing policy. The preliminary results show that the in-
crease in job satisfaction, elevated professional status and
better use of pharmacists’ skills were the most important
factors when deciding to become a prescriber. When asked
about concerns they may have regarding the implementa-
tion of the policy, pharmacists stated that access to patient
medical records and documentation of the consultation
were paramount. Coping with heavy workloads and staffing
issues to clear time for consultations and keeping up to
date are additional challenges prescribing pharmacists have
to face. Thus to overcome the barriers to prescribing, there
needs to be more support (financial and logistical) given to
pharmacists who wish to prescribe. In order to resolve re-
sistance from other prescribers and eliminate the potential
for boundary conflicts, there is a need for a clarification of
the pharmacist prescriber’s role and the fostering of
collaborative relationships to allow smooth integration
of pharmacist prescribing into practice.
It is not possible to map out in advance an optimal
and desirable path for the policy process, and the path is
decided by political processes and tradeoffs between
different stakeholder groups as they try to achieve a
change or to preserve the institutional environment
and institutional arrangements in order to suit their
interests and advance their own agendas [99]. Thus,
an understanding of the potential roles of the stake-
holders and the institutions involved in order to iden-
tify a potential coalition of support for the policy is
paramount for the success of the policy’s implementa-
tion and evaluation. Achieving a system-wide practice
change is a challenge that the profession of pharmacy
continues to face.
Endnotes
1Occasionally, the first two models co-exist. For ex-
ample, in New Mexico, pharmacists are primarily inde-
pendent prescribers. An exception to this is the “Naloxone
rescue kit”, which pharmacists can prescribe dependently.
In Washington State, there are thousands of different
protocol-based prescribed therapies, one of which is the
emergency contraceptive pill [59, 100]. There are now at
least 46 U.S. states that allow prescribing by protocol
and several states that allow at least some degree of
independent prescribing [for this additional information
I would like to thank the blind reviewer].
2Though there is no direct, explicit mandate for involving
patients in decisions relevant to their health in Israeli law,
the requisite conditions are encapsulated in the Patients’
Rights Law of 1996.
3Personal interviews, Jan-March 2015. All interviews
were confidential; the names of the interviewees are with-
held by mutual agreement
4Personal interviews, Jan-March 2015. All interviews
were confidential; the names of the interviewees are with-
held by mutual agreement.
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